专访院士黄璐琦:中医药正深度介入新冠肺炎诊疗全过程

2020-03-05 佚名 中国新闻网

关口前移,重心下沉,早期介入,全程干预,在中国工程院院士、中国中医科学院院长黄璐琦看来,中医药正在深度介入新冠肺炎诊疗全过程。从1月24日率领第一支国家中医医疗队奔赴武汉市金银潭医院至今,黄璐琦和他的团队已在武汉抗“疫”一线坚守40余天。谈及中医药在此次抗击新冠肺炎疫情中如何凸显所长,黄璐琦在接受中新社记者专访时称,中医药全面、全程参与防控救治,对改善症状、加快核酸转阴、促进恢复出院等均有很好效果

关口前移,重心下沉,早期介入,全程干预,在中国工程院院士、中国中医科学院院长黄璐琦看来,中医药正在深度介入新冠肺炎诊疗全过程。

从1月24日率领第一支国家中医医疗队奔赴武汉市金银潭医院至今,黄璐琦和他的团队已在武汉抗“疫”一线坚守40余天。

谈及中医药在此次抗击新冠肺炎疫情中如何凸显所长,黄璐琦在接受中新社记者专访时称,中医药全面、全程参与防控救治,对改善症状、加快核酸转阴、促进恢复出院等均有很好效果。

武汉市金银潭医院是一家专门收治新冠肺炎危重症患者的医院。初到金银潭医院,两大问题摆在黄璐琦面前,一是中西医治疗理念的沟通,另一方面则是当时中药药品的严重不足。

病区布局、人员调配、药品保障……5天后,金银潭医院将南一区病房的医疗工作正式交给黄璐琦所带领的医疗队,这也是疫情发生后第一个接管重症病区的中医医疗队。针对医院中药药品不足的现状,医疗队迅速搭建中药供应保障平台,保证医院药品供应。

“接管病区奠定了中医药防控新型冠状病毒肺炎的基础”,黄璐琦说,当时医疗队主管的32张病床开辟了中医药防控新冠肺炎的“战场”,使中医药能够与西医同台合作。

从中医角度来看,新冠肺炎属于“疫”病范畴,治疗方法上注重“正气存内,邪不可干,扶正气,辟邪毒”。黄璐琦认为,在新冠肺炎感染早期,中医药治疗方法对集中隔离、症状上已经有明显体现的患者,能够缩短病程,减少重症发生率,真正把关口前移。

1月23日,中西医结合治疗方案纳入了中国国家卫健委发布的第三版新冠肺炎诊疗方案。3月4日发布的最新版诊疗方案中,由黄璐琦及团队根据临床不断优化的“化湿败毒方”被列入新冠肺炎重型患者推荐用药处方。

临床疗效才是评价中医药优势的金标准。”黄璐琦介绍,随着医院及患者对中医药的逐渐认可,医疗队接管的武汉金银潭医院南一病区床位由32张增加到目前的43张,收治的均为重症患者,其它病区也开始陆续服用中药。

截至3月3日,该团队共收治新冠肺炎患者121例,其中中医辨证纯中药治疗出院40例、中西医结合治疗出院30例。所收治新冠肺炎重症患者的病情好转率(危重、重症转归)达到83.61%。
 
黄璐琦介绍,中西医结合组核酸转阴时间显着降低,发热、咳嗽、咽干、食欲减退、心慌等10个症状也明显改善,对淋巴细胞、中性粒细胞的指标改善起到积极作用,并且中西医结合治疗的患者平均住院时间显着缩短。

“中医不仅讲究‘未病先防’,也注重‘既病防复’,康复期患者的恢复更能体现中医药的优势”。黄璐琦介绍,重症出院患者整体临床症状显着改善,但多数患者仍存在不同程度肺部炎症、咳嗽、乏力、食欲不振等。中医对肺功能的康复已经有成熟的方法,包括呼吸的训练,比如调气、采气、养气、练气,还有耐力、排痰、放松的训练等。

目前黄璐琦和他的团队已为出院患者配上了恢复期的中药,并给予了康复期的指导,形成了一套完善的改善肺功能的方法和技术,患者症状明显减轻,改善率达到70%,患者回访效果满意。

“此次疫情的防治工作是中西医结合治疗的一次生动实践”,在黄璐琦看来,坚持“中西医并重”,加强中医药在治疗疾病全流程的深度参与,与西医形成优势互补、协同作战是打赢此次疫情医疗救治的关键。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2032640, encodeId=e784203264027, content=<a href='/topic/show?id=a26466120ab' target=_blank style='color:#2F92EE;'>#深度介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66120, encryptionId=a26466120ab, topicName=深度介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Oct 11 19:56:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703334, encodeId=c7091e0333451, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Wed Jun 17 07:56:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009412, encodeId=61492009412a3, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon May 18 05:56:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409996, encodeId=be541409996a0, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585279, encodeId=dc1015852e9fe, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027343, encodeId=400b102e343f1, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049185, encodeId=1c581049185ea, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049728, encodeId=88781049e28cb, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2032640, encodeId=e784203264027, content=<a href='/topic/show?id=a26466120ab' target=_blank style='color:#2F92EE;'>#深度介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66120, encryptionId=a26466120ab, topicName=深度介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Oct 11 19:56:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703334, encodeId=c7091e0333451, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Wed Jun 17 07:56:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009412, encodeId=61492009412a3, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon May 18 05:56:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409996, encodeId=be541409996a0, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585279, encodeId=dc1015852e9fe, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027343, encodeId=400b102e343f1, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049185, encodeId=1c581049185ea, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049728, encodeId=88781049e28cb, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2032640, encodeId=e784203264027, content=<a href='/topic/show?id=a26466120ab' target=_blank style='color:#2F92EE;'>#深度介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66120, encryptionId=a26466120ab, topicName=深度介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Oct 11 19:56:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703334, encodeId=c7091e0333451, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Wed Jun 17 07:56:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009412, encodeId=61492009412a3, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon May 18 05:56:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409996, encodeId=be541409996a0, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585279, encodeId=dc1015852e9fe, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027343, encodeId=400b102e343f1, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049185, encodeId=1c581049185ea, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049728, encodeId=88781049e28cb, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2032640, encodeId=e784203264027, content=<a href='/topic/show?id=a26466120ab' target=_blank style='color:#2F92EE;'>#深度介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66120, encryptionId=a26466120ab, topicName=深度介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Oct 11 19:56:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703334, encodeId=c7091e0333451, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Wed Jun 17 07:56:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009412, encodeId=61492009412a3, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon May 18 05:56:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409996, encodeId=be541409996a0, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585279, encodeId=dc1015852e9fe, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027343, encodeId=400b102e343f1, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049185, encodeId=1c581049185ea, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049728, encodeId=88781049e28cb, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
    2020-03-07 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=2032640, encodeId=e784203264027, content=<a href='/topic/show?id=a26466120ab' target=_blank style='color:#2F92EE;'>#深度介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66120, encryptionId=a26466120ab, topicName=深度介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Oct 11 19:56:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703334, encodeId=c7091e0333451, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Wed Jun 17 07:56:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009412, encodeId=61492009412a3, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon May 18 05:56:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409996, encodeId=be541409996a0, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585279, encodeId=dc1015852e9fe, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027343, encodeId=400b102e343f1, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049185, encodeId=1c581049185ea, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049728, encodeId=88781049e28cb, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2032640, encodeId=e784203264027, content=<a href='/topic/show?id=a26466120ab' target=_blank style='color:#2F92EE;'>#深度介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66120, encryptionId=a26466120ab, topicName=深度介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Oct 11 19:56:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703334, encodeId=c7091e0333451, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Wed Jun 17 07:56:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009412, encodeId=61492009412a3, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon May 18 05:56:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409996, encodeId=be541409996a0, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585279, encodeId=dc1015852e9fe, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027343, encodeId=400b102e343f1, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049185, encodeId=1c581049185ea, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049728, encodeId=88781049e28cb, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
    2020-03-06 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2032640, encodeId=e784203264027, content=<a href='/topic/show?id=a26466120ab' target=_blank style='color:#2F92EE;'>#深度介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66120, encryptionId=a26466120ab, topicName=深度介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Oct 11 19:56:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703334, encodeId=c7091e0333451, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Wed Jun 17 07:56:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009412, encodeId=61492009412a3, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon May 18 05:56:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409996, encodeId=be541409996a0, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585279, encodeId=dc1015852e9fe, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027343, encodeId=400b102e343f1, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049185, encodeId=1c581049185ea, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049728, encodeId=88781049e28cb, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
    2020-03-06 junJUN

    院士是学术至高点,也是大家必争之地呀

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2032640, encodeId=e784203264027, content=<a href='/topic/show?id=a26466120ab' target=_blank style='color:#2F92EE;'>#深度介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66120, encryptionId=a26466120ab, topicName=深度介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Oct 11 19:56:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703334, encodeId=c7091e0333451, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Wed Jun 17 07:56:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009412, encodeId=61492009412a3, content=<a href='/topic/show?id=51b429e159a' target=_blank style='color:#2F92EE;'>#全过程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29715, encryptionId=51b429e159a, topicName=全过程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon May 18 05:56:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409996, encodeId=be541409996a0, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585279, encodeId=dc1015852e9fe, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sat Mar 07 13:56:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027343, encodeId=400b102e343f1, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049185, encodeId=1c581049185ea, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049728, encodeId=88781049e28cb, content=中医中药,大多被人诋毁,不过梅斯里总是客观公正的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=运动yd, createdTime=Fri Mar 06 01:56:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
    2020-03-06 运动yd

    中医中药,大多被人诋毁,不过梅斯里总是客观公正的

    0

相关资讯

黄璐琦院士:中药标准不断提升

第十九届中国科协年会24日至26日在长春召开,中国工程院院士、中国中医科学院常务副院长黄璐琦在年会上指出,当代中医药的主旋律是创新和发展,近几年中医中药标准不断提升,已经开始引领中医药走向世界。黄璐琦表示,整个中药材产业现在的发展状态,跟国家的经济发展相一致。中成药工业增长速度从过去21.1%,逐步下降到2015年的5.69%,中药饮片从过去26.9%,下降到2015年不到7.88%,面临着一个结